Non-alcoholic fatty liver disease (NAFLD) is the fastest growing cause of chronic liver disease among patients with inflammatory bowel diseases (IBD). Studies have suggested that patients with IBD develop NAFLD with fewer metabolic risk factors than those without IBD. Data have also suggested associations between NAFLD and factors inherent to IBD such as disease activity, disease duration, and prior IBD surgery. Despite this complex relationship, the impact of NAFLD on clinical outcomes in IBD patients has not been examined on a large scale.